Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

α-Synuclein overexpression increases the tropism of pre-formed fibrils and MSA-patient derived seeds towards oligodendroglia.

Acta neuropathologica communications·2026
Same author

Long-Term Outcomes From a Decade of Donation After Circulatory Death Heart Transplantation in Australia.

JACC. Heart failure·2026
Same author

Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease.

Science advances·2026
Same author

Creutzfeldt-Jakob disease is an Alzheimer's disease-related dementia.

Trends in molecular medicine·2026
Same author

Single-nucleus brain transcriptomics reveals microglia dysfunction in multiple system atrophy.

Nature communications·2026
Same author

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

薬物開発

Suelyn Koerich1, Santiago Ramirez1, Natalia Astudillo1

  • 1The University of Texas Health Science Center at Houston, Houston, TX, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ

血漿交換（PE）は、進行したアルツハイマー病（AD）のマウスにおいて、アミロイドプラークと脳の炎症を軽減しました。これは、PEが脳からアミロイドβ（Aβ）を除去するのに役立つ可能性を示唆しており、AD治療のためのさらなる調査に値します。

科学分野:

  • 神経科学
  • 免疫学
  • 生化学

背景:

  • アルツハイマー病（AD）は認知症の主な原因であり、アミロイドプラーク、神経原線維変化、神経炎症を特徴としています。
  • アミロイドプラークを標的とする現在のAD治療法は、適格性とリスクベネフィットプロファイルに限界があります。
  • 末梢戦略は、脳のAβおよびタウ病理、神経炎症に影響を与える可能性について探求されています。

研究 の 目的:

  • 血漿交換（PE）のアルツハイマー病（AD）マウスモデルにおけるアミロイド病理と神経炎症を軽減する有効性を調査すること。
  • 脳および血漿におけるアミロイドβ（Aβ）沈着と炎症マーカーに対するPEの影響を評価すること。

主な方法:

  • 11ヶ月齢のAPP/PS1マウスに毎月PE処置を施しました。
  • 組織学的分析により、アミロイド沈着（チオフラビンS、4G8）および神経炎症マーカー（Iba-1、GFAP）を定量化しました。
  • ELISAおよびLuminexアッセイにより、脳ホモジネートおよび血漿中のAβレベルとサイトカイン濃度を測定しました。

主要な成果:

  • PEは治療されたマウスの皮質におけるアミロイドプラークの数と面積を有意に減少させました。
  • PEは脳におけるミクログリア（Iba-1）およびアストロサイト（GFAP）の活性化を減少させました。
キーワード:
アルツハイマー病アミロイドプラーク血漿交換神経炎症マウスモデル

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451
  • 生化学的分析により、PE治療マウスの脳では不溶性Aβ1-40およびAβ1-42レベルが低下し、炎症性サイトカインプロファイルが調節されていることが明らかになりました。

    • 結論:

    • 血漿交換は、進行したADマウスモデルにおいて、脳のアミロイド負担を軽減し、神経炎症を調節する可能性を示しています。
    • PE後の血漿Aβレベルの上昇は、脳から末梢へのAβクリアランスのメカニズムを示唆しています。
    • PEのAβクリアランスおよび抗炎症効果のメカニズムを完全に解明するには、さらなる研究が必要です。